ReviewExpert opinion on drug metabolism & toxicology2008
Efavirenz--still first-line king?
Review in Expert opinion on drug metabolism & toxicology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.Viruses · 2023Pooled it
- Trial
- Demographic and Socioeconomic Factors Associated With ART Nonadherence Among 15 Years and Older South Africans. Evidence From the 2022 Cross-Sectional Population-Based Household Survey.AIDS research and treatment · 2026Article
- Exploring Potential for Repurposing Antiretroviral Drugs Etravirine and Efavirenz in Prostate and Bladder Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The Future of Medicine: AI and ML Driven Drug Discovery Advancements.Current topics in medicinal chemistry · 2025Review
- Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease Therapeutics.ACS pharmacology & translational science · 2024Review
- Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model.International journal of molecular sciences · 2023Article
- Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96.The Lancet regional health. Western Pacific · 2023Article
- Efavirenz: History, Development and Future.Biomolecules · 2022Review
- Inclusion Compound of Efavirenz and γ-Cyclodextrin: Solid State Studies and Effect on Solubility.Molecules (Basel, Switzerland) · 2021Article
- Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections.AAPS PharmSciTech · 2021Review
- Synthesis of spirooxindolocarbamates based on Betti reaction: antibacterial, antifungal and antioxidant activities.Molecular diversity · 2020Article
- Organic carbamates in drug design and medicinal chemistry.Journal of medicinal chemistry · 2015Review
- Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.Clinical pharmacokinetics · 2015Article
- Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Pediatric health, medicine and therapeutics · 2014Article
- In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Antimicrobial agents and chemotherapy · 2013Article
- The HIV antiretroviral drug efavirenz has LSD-like properties.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.Journal of the International AIDS Society · 2013Review
- Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.In silico pharmacology · 2013Article
- A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs.Journal of molecular modeling · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEfavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended as initial therapy. Recently, several new antiretroviral drugs, including second generation NNRTIs, protease-inhibitors, an integrase-inhibitor and a CCR5 inhibitor, have become or will be shortly available.
objectiveThis article will review relevant efficacy and safety data of efavirenz compared to these novel agents or certain common alternate drugs currently used as initial therapy in treatment-naive patients.
methodsPublished articles and conference presentations pertaining to efavirenz and/or the newer antiretroviral agents were evaluated. RESULTS/
conclusionsEfavirenz will continue to be preferred initial therapy for now. If longer-term studies of integrase inhibitors and second-generation NNRTIs confirm initial findings, they will eventually supplant efavirenz as preferred first-line agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.